(ABEO) Abeona Therapeutics - Overview
Stock: Gene Therapy, Cell Therapy, Skin Disorder, Eye Disorder, AAV Vector
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 61.8% |
| Relative Tail Risk | -17.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.06 |
| Alpha | -25.13 |
| Character TTM | |
|---|---|
| Beta | 0.707 |
| Beta Downside | 0.522 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.48% |
| CAGR/Max DD | 0.44 |
Description: ABEO Abeona Therapeutics December 30, 2025
Abeona Therapeutics (NASDAQ:ABEO) is a clinical-stage biotech focused on gene- and cell-based therapies for rare, life-threatening disorders. Its flagship program, pz-cel, is an autologous, cell-based gene therapy targeting recessive dystrophic epidermolysis bullosa (RDEB), a condition with no approved treatments and an estimated U.S. patient pool of roughly 1,500 individuals.
Beyond pz-cel, Abeona is advancing a pipeline of AAV-based candidates-including ABO-503 for X-linked retinoschisis, ABO-504 for Stargardt disease, and ABO-505 for autosomal dominant optic atrophy-leveraging its proprietary AIM vector platform. As of the latest 10-Q, the company reported cash and cash equivalents of approximately $150 million, giving it a runway of about 18 months at current burn rates, while R&D expenses have risen ~35 % YoY, reflecting intensified trial activity.
The gene-therapy sector is benefitting from a projected 15 % CAGR through 2030, driven by expanding FDA approvals and favorable reimbursement trends, but competition for rare-disease indications remains intense, and any setback in pivotal trials could materially affect valuation. For a deeper quantitative view, you may want to explore ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 82.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA 6.29 > 1.0 |
| NWC/Revenue: 3743 % < 20% (prev 3337 %; Δ 405.8% < -1%) |
| CFO/TA -0.32 > 3% & CFO -74.9m > Net Income 82.3m |
| Net Debt (-59.1m) to EBITDA (89.8m): -0.66 < 3 |
| Current Ratio: 9.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (54.2m) vs 12m ago 12.81% < -2% |
| Gross Margin: 57.95% > 18% (prev -0.36%; Δ 5831 % > 0.5%) |
| Asset Turnover: 2.95% > 50% (prev 2.34%; Δ 0.61% > 0%) |
| Interest Coverage Ratio: 21.99 > 6 (EBITDA TTM 89.8m / Interest Expense TTM 3.94m) |
Altman Z'' -14.01
| A: 0.84 (Total Current Assets 216.1m - Total Current Liabilities 22.2m) / Total Assets 231.1m |
| B: -3.12 (Retained Earnings -721.6m / Total Assets 231.1m) |
| C: 0.49 (EBIT TTM 86.6m / Avg Total Assets 175.8m) |
| D: -12.05 (Book Value of Equity -721.1m / Total Liabilities 59.9m) |
| Altman-Z'' Score: -14.01 = D |
Beneish M -0.79
| DSRI: 0.55 (Receivables 1.62m/1.61m, Revenue 5.18m/2.82m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 3.21 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.83 (Revenue 5.18m / 2.82m) |
| TATA: 0.68 (NI 82.3m - CFO -74.9m) / TA 231.1m) |
| Beneish M-Score: -0.79 (Cap -4..+1) = D |
What is the price of ABEO shares?
Over the past week, the price has changed by -0.77%, over one month by -1.16%, over three months by +21.28% and over the past year by -11.86%.
Is ABEO a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ABEO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.6 | 302.3% |
| Analysts Target Price | 20.6 | 302.3% |
| ValueRay Target Price | 5.3 | 2.7% |
ABEO Fundamental Data Overview February 04, 2026
P/E Forward = 500.0
P/S = 700.4233
P/B = 1.614
Revenue TTM = 5.18m USD
EBIT TTM = 86.6m USD
EBITDA TTM = 89.8m USD
Long Term Debt = 10.9m USD (from longTermDebt, last quarter)
Short Term Debt = 8.99m USD (from shortTermDebt, last quarter)
Debt = 24.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -59.1m USD (from netDebt column, last quarter)
Enterprise Value = 96.8m USD (280.2m + Debt 24.1m - CCE 207.5m)
Interest Coverage Ratio = 21.99 (Ebit TTM 86.6m / Interest Expense TTM 3.94m)
EV/FCF = -1.18x (Enterprise Value 96.8m / FCF TTM -82.4m)
FCF Yield = -85.06% (FCF TTM -82.4m / Enterprise Value 96.8m)
FCF Margin = -1589 % (FCF TTM -82.4m / Revenue TTM 5.18m)
Net Margin = 1589 % (Net Income TTM 82.3m / Revenue TTM 5.18m)
Gross Margin = 57.95% ((Revenue TTM 5.18m - Cost of Revenue TTM 2.18m) / Revenue TTM)
Gross Margin QoQ = none% (prev 75.0%)
Tobins Q-Ratio = 0.42 (Enterprise Value 96.8m / Total Assets 231.1m)
Interest Expense / Debt = 3.74% (Interest Expense 901.0k / Debt 24.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = 68.4m (EBIT 86.6m * (1 - 21.00%))
Current Ratio = 9.74 (Total Current Assets 216.1m / Total Current Liabilities 22.2m)
Debt / Equity = 0.14 (Debt 24.1m / totalStockholderEquity, last quarter 171.2m)
Debt / EBITDA = -0.66 (Net Debt -59.1m / EBITDA 89.8m)
Debt / FCF = 0.72 (negative FCF - burning cash) (Net Debt -59.1m / FCF TTM -82.4m)
Total Stockholder Equity = 105.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 46.83% (Net Income 82.3m / Total Assets 231.1m)
RoE = 78.38% (Net Income TTM 82.3m / Total Stockholder Equity 105.1m)
RoCE = 74.71% (EBIT 86.6m / Capital Employed (Equity 105.1m + L.T.Debt 10.9m))
RoIC = 54.97% (NOPAT 68.4m / Invested Capital 124.4m)
WACC = 8.08% (E(280.2m)/V(304.3m) * Re(8.52%) + D(24.1m)/V(304.3m) * Rd(3.74%) * (1-Tc(0.21)))
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 45.69%
Fair Price DCF = unknown (Cash Flow -82.4m)
EPS Correlation: 55.10 | EPS CAGR: 190.3% | SUE: 0.10 | # QB: 0
Revenue Correlation: -17.23 | Revenue CAGR: -80.30% | SUE: -3.27 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.07 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=+48.1% | Growth Revenue=+1753.5%